- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00917293
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Comparative Study to Evaluate the Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia in Patients With Schizophrenia and Schizoaffective Disorders
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will assess the effect of Pyridoxal 5'-Phosphate on the reduction of expressed symptoms of moderate to severe tardive dyskinesia in patients with schizophrenia and schizoaffective disorders who are on a stable dose, and regime, of either a long acting (i.e. depot/IM) or oral antipsychotic medication, as compared to placebo.
Symptoms will be assessed through the administration and scoring of Abnormal Involuntary Movement Scale (AIMS), specifically on items 1 through 7 (facial and oral movements, extremity movements and trunk movements) at each visit.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8R 4Z3
- Vancouver Island Health Authority
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 1R8
- Centre for Addiction and Mental Health
-
Windsor, Ontario, Canada, N9C 3Z4
- Windsor Regional Hospital
-
-
-
-
TamilNadu
-
Chennai, TamilNadu, India, 600101
- Schizophrenia Research Foundation (SCARF) Mental Health Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have signed an informed consent document indicating that they understand the purpose of the study, its objectives, and the expectations of participation in the study and that they agree to participate in the study.
- Meet current diagnostic criteria for Schizophrenia (Disorganized [295. 10], Paranoid [295.30], or Residual [295.60]), or Schizoaffective Disorder [295.70] as defined by the DSM-IV for at least 3 months before screening.
- Have been on a stable dose and regime of a LAI for at least 3 injection intervals or oral antipsychotic for at least 1 month prior to randomization and are expected to remain on this stable dose and regime throughout their participation in the study.
- Meet current diagnostic criteria for Neuroleptic Induced Tardive Dyskinesia [333.82] as defined by the DSM-IV.
- Scoring ≥3 (moderate) on item 8, the "severity of abnormal movements overall" section of the AIMS.
- Score ≥3 (moderate) on at least one item, or ≥2 (mild) on at least 2 items, and an overall total score of ≥5 on items 1 through 7 (facial and oral movements, extremity movements and trunk movements) sections of the AIMS.
- Female patients must be post-menopausal for at least 2 years or surgically sterile. Women of childbearing potential must be using or agree to use a reliable form of contraception before entry into and during participation in the study. Reliable contraception can include an oral or other hormonal contraceptive started at least 4 weeks prior to randomization, a barrier method such as condoms or a diaphragm used with spermicide, or an intrauterine device (IUD).
- Patients must be capable of administering study medication themselves or will have assistance with the administration of the study medication consistently available throughout the study.
Exclusion Criteria:
- Involuntarily committed to a psychiatric hospital or correctional facility.
- A primary active DSM-IV diagnosis or co-morbid Axis 1 diagnosis other than schizophrenia or schizoaffective disorder.
- PANSS Score > than 120 at the screening visit.
- Current medical diagnosis that which could confound the interpretation or evaluation of the indication under study (i.e. Parkinson's Disease, Huntington's Chorea, Muscular Dystrophy, Tourette's Syndrome).
- History of liver cirrhosis, chronic active hepatitis (known positive serum test within 6 months of enrollment) or severe liver dysfunction, or liver transaminase ≥3 times ULN at screening (or obtained within 30 days prior to screening visit)
- History of malignancy during the last 5 years.
- Pregnant or any woman of childbearing potential who is not using a reliable form of contraception (this can include an oral or other hormonal contraceptive started at least 4 weeks prior to randomization, a barrier method such as condoms or a diaphragm used with spermicide, or an intrauterine device (IUD)). Women who have been post-menopausal for at least two years or who have undergone surgical sterilization are considered to be not of childbearing potential.
- Any medical, such as unstable cardiovascular, respiratory, neurological, renal, hepatic, immunological or endocrine, or psychiatric condition which in the opinion of the investigator makes the patient an unsuitable candidate for the study.
- History of any pre-existing gastrointestinal narrowing or inability to swallow the oral study medication whole with the aid of water.
- Male and female patients with a BMI of ≥20.
- Significant, ongoing alcohol or drug dependency within 3 months before screening as defined by the DSM-IV (nicotine will not be exclusionary).
- Significant risk of suicide or violent behavior as clinically assessed by the investigator.
- Participation in any other investigational drug or device study within 30 days of randomization.
- Patients who have previously participated in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pyridoxal 5'-Phosphate
Pyridoxal 5'-Phosphate, enteric-coated 2x 250mgs po bid.
|
Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.
Other Names:
|
Placebo Comparator: Placebo
Placebo 2 pills, po bid.
|
Placebo 2 pills, po bid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary outcome measure will be a reduction in the total AIMS score for items 1 through 7 (facial and oral movements, extremity movements and trunk movements) across treatment groups. .
Time Frame: From baseline through to week 12
|
From baseline through to week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
An AIMS score reduction (items 1-7) across arms over course of study amongst completers; determine whether the proportion of responders differs between treatment arms; a reduction in the AIMS score, items 1 - 7 total, across treatment arms.
Time Frame: From baseline through to Week 12 and Baseline compared to Week 12
|
From baseline through to Week 12 and Baseline compared to Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gary J. Remington, MD, PhD, Centre for Addiction and Mental Health
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08030
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tardive Dyskinesia
-
Neurocrine BiosciencesCompletedTardive Dyskinesia (TD)United States, Puerto Rico
-
GGZ CentraalUniversity Medical Center Groningen; Maastricht UniversityTerminatedTardive Dyskinesia | Tardive DystoniaNetherlands
-
Synchroneuron Inc.WithdrawnDrug-induced Tardive DyskinesiaUnited States
-
Centre for Addiction and Mental HealthMerck KGaA, Darmstadt, GermanyTerminatedNeuroleptic-induced Tardive DyskinesiaCanada, India
-
Taoyuan Psychiatric Center, Ministry of Health...Department of HealthCompletedNeuroleptic-Induced Tardive DyskinesiaTaiwan
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Neurocrine BiosciencesCompletedTardive DyskinesiaUnited States
-
Shanghai Mental Health CenterUnknownTardive DyskinesiaChina
-
Neurocrine BiosciencesEvideraUnknownTardive DyskinesiaUnited States
-
Neurocrine BiosciencesCompletedTardive DyskinesiaUnited States, Puerto Rico
Clinical Trials on Pyridoxal 5'-Phosphate
-
MedicureCompletedMyocardial Ischemia | Reperfusion Injury | Coronary Artery Bypass Graft Surgery | Myocardial RevascularizationCanada, United States
-
MedicureCompletedMyocardial Ischemia | Reperfusion Injury | Coronary Artery Bypass Graft SurgeryCanada, United States
-
Carolina Musculoskeletal InstituteBaylor University; Pamlab, L.L.C.CompletedDiabetic Peripheral NeuropathyUnited States
-
University of ReadingINNOPURENot yet recruitingAutismUnited Kingdom
-
Trieu, Nguyen Thi, M.D.Completed
-
MedicureCompletedHypertension | Metabolic Syndrome | Diabetes Mellitus Type 2Canada
-
MedicureRecruitingPyridox(am)Ine 5'-Phosphate Oxidase DeficiencyUnited States, Australia
-
Colorado State UniversityCompletedReceptor BlockadeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPrimary Myelofibrosis | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential ThrombocythemiaUnited States
-
Egetis TherapeuticsSolasia Pharma K.K.TerminatedColorectal Cancer | Chemotherapy-induced Peripheral NeuropathyFrance, Korea, Republic of, United States, Italy, United Kingdom, Hong Kong, Spain, Hungary, Belgium, Japan, Germany, Czechia, Taiwan